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Abstract
Introduction Early treatment remains the most effective HIV prevention strategy; poor linkage to care after HIV diagnosis 
may compromise this benefit. We sought to better understand patient characteristics and their association with virological 
suppression (VS) following cART initiation.
Methods The TAK project collects pre-linkage to care and clinical data on patients diagnosed with HIV in voluntary test-
ing facilities in central Poland. Data collected for persons diagnosed in 2010–2013 were linked with HIV clinic records. 
Individuals linked to care who commenced cART were followed from until the earliest of first VS (HIV RNA < 50 copies/
ml), last visit, death or 6 January 2016. Cox-proportional hazard models were used to identify factors associated with first 
viral suppression.
Results 232 persons were HIV positive, 144 (62%, 95% CI 55, 68%) linked to care, 116 (81% of those linked to care, 95% 
CI 73, 87%) started cART during follow up, of which 113 (97%, 95% CI 93, 99%) achieved VS. Non-PI based regimen (for 
integrase inhibitors aHR: 5.03: 1.90, 13.32) and HLA B5701-positive (aHR: 3.97: 1.33, 11.85) were associated with higher 
chance of VS. Unknown syphilis status (aHR: 0.27: 0.13, 0.57) and higher HIV RNA (aHR a tenfold increase: 0.56: 0.42, 
0.75) remained associated with lower chance of VS.
Conclusions Although a low proportion of persons were linked to care, almost all those linked to care started cART and 
achieved rapid VS. The high rates of VS were irrespective of prior HIV-associated risk behaviours. Linkage to care remains 
the highest priority in prevention strategies in central Poland.
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Introduction
Combination antiretroviral therapy (cART) remains the most 
effective HIV prevention strategy, if persons with HIV infec-
tion are identified, linked to care and receive effective treat-
ment [1, 2]. To significantly reduce the impact of the HIV 
epidemic, UNAIDS has set the target of achieving at least 
90% of persons with HIV diagnosed, 90% of those diag-
nosed to be linked to care and 90% of those linked to care 
on effective cART by 2020 [3, 4]. The cascade of care is a 
straightforward and simple summary of the sequential stages 
of HIV medical care for people living with HIV; and can be 
used to identify stages in care to be targeted to curb the epi-
demic across the whole range of interventions [5, 6]. While 
the left side of the cascade describes the actions taken for 
screening for HIV, the right side provides information on 
effectiveness of treating those who are diagnosed. Taken 
together, the cascade of care has the power to show the effec-
tiveness of collaboration between public health institutions 
and medical care providers. This area has been identified 
as a weak spot for many European countries, especially for 
Central and Eastern Europe [7].
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In our earlier work, we have identified that over 40% of 
the patients diagnosed in voluntary counselling and testing 
facilities (VCTs) in central Poland were not linked to care, 
and this situation did not change during the 4 years of obser-
vation [8, 9]. In the present study, our aim was to construct 
a cascade of care for central Poland. In addition, we investi-
gate the rate of viral suppression, as well as pre-linkage and 
clinical factors related to it.
Materials and methods
The TAK project collects information on patients diagnosed 
with HIV in VCTs in central Poland, follows their linkage to 
care and ongoing routine clinical care [10]. Data collected 
for persons diagnosed in 2010–2013 in VCTs were linked 
with HIV clinic records using the western blot test num-
ber as a unique identifier. This allows for persons who test 
positive for HIV to be followed throughout linkage to care 
and ongoing routine clinical care following their diagnosis. 
Persons linked to care are managed in accordance with the 
Polish AIDS Society recommendations [11].
Cascade of care
To set the scene, a complete cascade of care was constructed 
using the TAK information. The proportion of people living 
with HIV in Poland (both diagnosed and undiagnosed) is 
unknown; therefore, the first stage in the cascade was con-
sidered to be those who tested positive for HIV at the VCTs 
(100%). The subsequent stages of the cascade are shown as 
both percentages according to those who tested positive for 
HIV (fixed denominator), as well as step wise percentages, 
i.e., the percentages of HIV-positive people who were linked 
to care, of those linked to care who started cART, and of 
those who started cART who achieved VS.
Factors associated with the final stage 
of the cascade: virological suppression in those who 
started cART 
For the second component of the project, baseline was 
defined as the date of first cART, defined as three or more 
antiretroviral drugs including integrase inhibitor (InSTI), 
protease inhibitor (PI) or non-nucleoside reverse tran-
scriptase inhibitors (NNRTI). People were followed from 
baseline until first viral suppression, defined as HIV RNA 
< 50 copies/ml, or censored at last visit, death or 6 Jan 2016, 
the administrative censoring date. Persons who did not have 
a HIV RNA and CD4+ count measured at cART start were 
excluded.
The distribution of variables at baseline were shown 
according to those who did and did not achieve viral 
suppression. Frequencies and percentages with Chi-squared 
tests are shown for categorical variables, and median and 
interquartile range (IQR) with Wilcoxon–Mann–Whitney 
tests are shown for continuous variables. Kaplan–Meyer 
curves were used to investigate the time to viral suppres-
sion in those who started cART overall as well as stratified 
by year of starting cART.
Univariate and multivariate Cox-proportional hazard 
models were used to identify factors measured at time of 
cART initiation which were associated with higher chance of 
viral suppression. Factors considered for inclusion included 
age, gender, nationality (Polish vs other), education (high 
vs lower/unknown), sexual orientation, HIV test location 
(VCTs vs other), number of HIV tests within the last year, 
partner’s HIV status, partner’s testing status, number of 
partners in last year and in the lifetime, condom use with 
stable partner, condom use with casual partners, having sex 
under the influence of drugs or alcohol, time to linkage to 
care, lymphocyte CD3+, CD4+ and CD8+ count, CD4+/
CD8+ ratio, year of first cART, HIV RNA at starting cART, 
syphilis, anti-HCV antibodies and anti-HBc total antibodies 
(HCV and HBV) status, HIV subtype, HLA B5701 geno-
type (positive vs negative) and cART regimen. Factors with 
P < 0.1 in univariate models were included in multivariate 
models, which were additionally adjusted for age. Factors 
with a frequency of < 5 in any level were not considered for 
inclusion in univariate or multivariate models.
Basic characteristics of those stopped treatment during 
follow up were compared according to drug class. Those 
who stopped were split according to those who switched 
regimens (defined as stopping the first regimen and starting 
the second within 7 days) and those who did not restart after 
stopping. The number and percent of people who stopped 
their initial regimen as well as the reason for stopping were 
reported.
The study was approved by the Bioethical Committee of 
the Medical University of Warsaw (AKBE/99/16). Informed 
consents were not collected due to the anonymous character 
of VCT testing.
Results
Two hundred and thirty-two persons were tested HIV posi-
tive at VCTs and 144 (62%, 95% CI 55, 68) linked to care 
(Fig. 1). Of those linked to care, 116 (81% 95% CI 73, 87) 
started cART during follow up, with a median time from 
linkage to care to starting cART of 6 (IQR 3–9) months. 
One hundred and thirteen (97%, 95% CI 93, 99%) persons 
achieved viral suppression in a median time of 5 (IQR 4–5) 
months (Fig. 2).The median survival time to viral sup-
pression has significantly reduced in more recent calendar 
years, from a median of 5.42 (95% CI 2.95, 4.89) months 
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in 2010/11, through 4.96 (95% CI 3.74, 6.74) in 2012 and 
4.54 (95% CI 3.06, 6.74) in 2013 to 2.17 (95% CI 1.87, 5.03) 
months in 2014/15 (Fig. 2, P = 0.01).
Of those who started cART 111 (96%) were men, 98 
(85%) were of homosexual orientation, 26 (22%) had a 
positive venereal disease research laboratory test (VDRL) 
at baseline, 34 (29%) had a partner who had never tested 
for HIV, 33 (28%) had a HIV-positive partner, 66 (57%) 
reported always using condoms with casual partners, and 24 
(21%) reported having sex on drugs or alcohol. The median 
age was 32 (IQR 28–37) years, lymphocyte CD4+ count 
was 353 (260–416) cells/µl and HIV RNA was 4.5 (3.9–5.1) 
log10 copies/ml at first starting cART (Table 1).
Unadjusted hazard ratios (HR) between both preclini-
cal and clinical factors and viral suppression are shown in 
Table 2. Those of bisexual orientation had an almost a three-
fold higher chance of achieving viral suppression relative 
to those of homosexual orientation (HR 2.97 95% CI 1.27, 
6.96). Those with no reported history of sex on drugs and 
alcohol (HR 1.63 95% CI 1.02, 2.61), HLA B5701 geno-
type (HR 5.12 95% CI 1.98, 13.26), later year of starting 
cART and a non-PI based regimen at the time of starting 
cART also had higher chance of achieving viral suppres-
sion. Unknown syphilis (HR 0.46 95% CI 0.25, 0.85), and 
a higher HIV RNA level (HR For a tenfold increase: 0.61 
95% CI 0.49, 0.75) were associated with lower chance of 
achieving viral suppression. Those who had one or more 
HIV tests within the last year (P = 0.078), of unknown HCV 
(P = 0.168) and HBV status (P = 0.064), relative to negative 
status relative to no disease were borderline associated with 
higher chance of viral suppression, and were also included 
in multivariate models.
Variables with P < 0.1 in univariate analysis (listed above) 
and age were adjusted for in multivariate analyses, and the 
Fig. 1  Cascade of care for TAK 
project
Fig. 2  Kaplan–Meier survival curve for time to viral suppression in those who start cART presented for all (left side) and by year of starting 
cART (right side)
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resulting adjusted HR (aHR) are shown in Table 2. Bisexual 
orientation relative to homosexual orientation (aHR 4.54 
95% CI 1.76, 11.68), a non-PI based regimen (particularly 
strong for integrase inhibitors aHR 5.03 95% CI 1.90, 13.32) 
and HLA B5701 positive (aHR 3.97 95% CI 1.33, 11.85) 
remained associated with higher chance of viral suppression. 
Unknown syphilis status (relative to no syphilis, aHR: 0.27 
95% CI 0.13, 0.57) and higher HIV RNA (aHR a tenfold 
Table 1  Characteristics of persons who were tested HIV positive at VCT, linked to care and started cART stratified by viral suppresion
Factors Total
N = 116
Viral suppression
No N = 3
Viral suppression
Yes N = 113
P value
Number (%)
Male gender 111 (95.7) 3 (100) 108 (95.6) 0.981
Polish nationality 112 (96.6) 3 (100) 109 (96.5) 0.983
High education 94 (81.0) 3 (100) 91 (80.5) 0.959
Sexual orientation
 Heterosexual 12 (10.3) 0 (0.0) 12 (10.6) 0.998
 Homosexual 98 (84.5) 3 (100) 95 (84.1)
 Bisexual 6 (5.2) 0 (0.0) 6 (5.3)
Last test at VCT 68 (58.6) 2 (66.7) 66 (58.4) 0.776
At least one HIV test within last year 85 (73.3) 3 (100) 82 (72.6) 0.951
Positive HBV status at first cART 14 (12.1) 0 (0.0) 14 (12.4) 0.996
Positive HCV status at first cART 3 (2.6) 0 (0.0) 3 (2.7) 0.999
Positive syphilis status at first cART 26 (22.4) 1 (33.3) 25 (22.1) 0.951
Partner tested for HIV 42 (36.2) 2 (66.7) 40 (35.4) 0.92
Partner HIV positive 33 (28.4) 2 (66.7) 31 (27.4) 0.18
Always using condom with stable partners 56 (48.3) 1 (33.3) 55 (48.7) 0.605
Always using condom with casual partners 66 (56.9) 1 (33.3) 65 (57.5) 0.421
Sex on drugs or alcohol 24 (20.7) 1 (33.3) 23 (20.4) 0.59
Time to linked to care
 < 1 month 89 (76.7) 3 (100) 86 (76.1) 0.996
 1–3 months 15 (12.9) 0 (0.0) 15 (13.3)
 >3 months 12 (10.3) 0 (0.0) 12 (10.6)
HIV Subtype
 A/CRF/OTHER 13 (11.2) 0 (0.0) 13 (11.5) 0.998
 B 87 (75.0) 3 (100) 84 (74.3)
 Unknown 16 (13.8) 0 (0.0) 16 (14.2)
Year of first cART 
 2010/11 24 (20.7) 1 (33.3) 23 (20.4) 0.988
 2012 28 (24.1) 1 (33.3) 27 (23.9)
 2013 39 (33.6) 1 (33.3) 38 (33.6)
 2014/15 25 (21.6) 0 (0.0) 25 (22.1)
cART regimen type
 PI 65 (56.0) 2 (66.7) 63 (55.8) 0.968
 NNRTI 44 (37.9) 1 (33.3) 43 (38.1)
 InSTI 7 (6.0) 0 (0.0) 7 (6.2)
Positive HLA B5701 5 (4.3) 0 (0.0) 5 (4.4) 0.981
Median(IQR)
 Age in years 31.6 (28.1, 37.3) 24.5 (23.3, 36.5) 31.6 (28.3, 37.4) 0.189
 HIV RNA (log10 copies/ml) 4.5 (3.9, 5.1) 5.1 (4.7, 5.7) 4.5 (3.9, 5.1) 0.122
 Lymphocytes CD4+ count (cells/mm3) 352.5 (259.5, 415.5) 523.0 (224.0, 574.0) 352.0 (265.0, 405.0) 0.361
 Number of casual partners (1 year) 3.5 (0.0, 3.5) 3.5 (1.0, 3.5) 0.823
 Number of partners (lifetime) 15.5 (8.0, 35.5) 15.5 (3.5, 35.5) 15.5 (8.0, 35.5) 0.746
 Time to linked to care (years) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.0 (0.0, 0.1) 0.146
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increase: 0.56 95% CI 0.42, 0.75) remained associated with 
lower chance of viral suppression. No association remained 
between number of HIV tests within the last year, year of 
starting cART, and reported sex on drugs or alcohol after 
adjustment for other factors (all P > 0.05).
Of the 116 people who started cART, 17 (15%) persons 
stopped their first regimen and 15 of 17 (13%) who stopped 
started a second regimen within 7 days. A summary of those 
who stopped their initial regimen is shown in Table 3. Of 
the 65 people who started on PI based regimen, 10 (15%) 
stopped treatment, followed by 7 (16%) of those who started 
NNRTI based regimen, and none of those who started InSTI. 
Reasons for stopping NNRTI included four (57%) due to 
hypersensitivity, two (29%) due to patient decision/non 
adherence, and one (14%) due to toxicity. Most (80%) of 
those who stopped PI were due to toxicity, one (10%) due 
to patient decision/non adherence and another one (10%) 
due to simplification of regimen. Of the two people who 
did not start a second regimen within 7 days of stopping, 
one was due to toxicity and one was due to patients decision 
Table 2  Unadjuste and adjusted 
hazard ratios for time to first 
viral suppression defined as 
HIV RNA < 50 after starting 
cART 
Variable Univariate Multivariate
HR (95% CI) P value P value HR (95% CI) P value P value
Age at starting cART 
 Per year older 0.86 (0.67, 1.10) 0.218 0.218 0.77 (0.54, 1.09) 0.138 0.138
Sexual orientation
 Heterosexual 0.89 (0.49, 1.62) 0.698 0.037 0.98 (0.44, 2.17) 0.964 0.007
 Homosexual Reference Reference
 Bisexual 2.97 (1.27, 6.96) 0.012 4.54 (1.76, 11.68) 0.002
Number of tests within last year
 None Reference 0.078 Reference 0.13
 1 or more 0.69 (0.45, 1.04) 0.078 0.68 (0.41, 1.12) 0.13
Year of first cART 
 2010/11 Reference 0.011 Reference 0.316
 2012 1.45 (0.82, 2.58) 0.203 1.80 (0.93, 3.50) 0.083
 2013 1.55 (0.90, 2.68) 0.116 1.50 (0.81, 2.77) 0.195
 2014/15 2.74 (1.50, 5.01) 0.001 1.22 (0.56, 2.66) 0.614
HBV status at first cART 
 Yes 0.84 (0.48, 1.49) 0.554 0.183 1.02 (0.47, 2.21) 0.957 0.708
 No Reference Reference
 Unknown/missing 0.59 (0.33, 1.04) 0.07 0.76 (0.39, 1.49) 0.432
HCV status at first cART 
 Yes 0.77 (0.24, 2.45) 0.663 0.168 1.95 (0.48, 7.86) 0.347 0.642
 No Reference Reference
 Unknown/missing 0.47 (0.22, 1.04) 0.064 1.12 (0.43, 2.92) 0.815
Syphilis status at first cART 
 Yes 0.83 (0.52, 1.31) 0.422 0.043 0.91 (0.55, 1.49) 0.702 0.003
 No Reference Reference
 Unknown/missing 0.46 (0.25, 0.85) 0.013 0.27 (0.13, 0.57) < 0.001
HIV RNA at starting cART 
 Per tenfold higher 0.61 (0.49, 0.75) < 0.001 < 0.001 0.56 (0.42, 0.75) < 0.001 < 0.001
Regimen type
 PI Reference < 0.001 Reference 0.003
 NNRTI 2.00 (1.34, 2.98) < 0.001 1.56 (0.95, 2.57) 0.079
 INSTI 2.87 (1.30, 6.35) 0.009 5.03 (1.90, 13.32) 0.001
Sex on drugs or alcohol
 No 1.63 (1.02, 2.61) 0.041 0.041 1.42 (0.83, 2.43) 0.199 0.199
 Yes Reference
HLA B5701
 No/Unknown Reference < 0.001
 Yes 5.12 (1.98, 13.26) < 0.001 3.97 (1.33, 11.85) 0.013 0.013
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or non-adherence (Table 3). Further information regarding 
specific toxicities was not available.
Discussion
In our study, four in ten people who tested HIV positive at 
the voluntary settings were not linked to care, but almost all 
those who were linked to care started cART and achieved 
rapid viral suppression during follow-up. In addition, most 
of the persons who started treatment in our study remained 
on the first cART regimen during the observation time.
Viral suppression remains the core factor in achieving 
treatment aims, namely reduction in morbidity/mortality and 
in HIV transmission. Therefore, we have investigated factors 
associated with the rate of viral suppression and identified 
bisexual orientation, HLA B5701 positivity and cART regi-
men to be significantly associated with faster rate of viral 
suppression. In earlier TAK analyses bisexual orientation 
was shown to be negatively associated with linkage to care 
[9]. In the survey study of sexual behaviours in 13 Euro-
pean cities, including Warsaw, men who have sex with men 
and women tended to be less open about their own sexual 
attraction as compared to men who have sex with men only. 
Furthermore, 60% of participants declared they would not 
openly admit their attraction to men [12]. This indicates 
that bisexual persons cannot be considered a homogene-
ous group, in terms of social behaviours. The association 
between bisexual orientation and faster viral suppression in 
the current study might be underpowered, as this group is 
represented by merely six persons in the studied population, 
and likely to disappear with a larger sample.
Recently there is a trend in focusing on key populations, 
defined as persons more likely to acquire or transmit HIV 
and it is considered that their engagement in prevention 
and educational programs is necessary for achieving better 
control over the HIV epidemic [13, 14]. The findings of 
the TAK project underlines that educational programs for 
the general population should not be omitted in order to 
decrease stigma and improve linkage to care and antiretro-
viral therapy intake. Although hetero- and bisexual mode of 
HIV transmission is far less frequent than homosexual, these 
two groups are at higher risk of not being linked to care thus 
remaining at risk of disease progression and HIV transmis-
sion [15]. In countries with high HIV fear and stigmatisation 
many persons with risky behaviour do not consider them-
selves at risk and do not spontaneously seek for information 
about HIV [16, 17].
In our study, both InSTI and NNRTI based regimens were 
associated with over twice faster rate of viral suppression 
as compared to PI based regiment, even after adjusting for 
other factors. The InSTI based regimen has been shown to 
have better efficacy and tolerability with lower treatment 
discontinuation rate as compared to PI-based regimens [18, 
19]. The findings on NNRTI in our study almost in all cases 
relate to rilpivirine co-formulated with emtricitabine and 
tenofovir in one pill. Therefore, the observed faster suppres-
sion rate may reflect better adherence to one-pill regimen 
[20]. The impact of HLA B5701 is well in line with our ear-
lier findings showing faster viral suppression after starting 
cART in persons with the presence of this allele, as well as 
with studies of long-term nonprogressors [21–23]. However, 
it needs to be underlined that other non-routinely tested HLA 
alleles, such as HLA B27 may play a role in natural control 
over viral replication.
Furthermore, we have identified a slower rate of viral sup-
pression in persons with higher baseline HIV RNA, which is 
a well identified factor for worse or slower response to cART 
[24]. The unknown syphilis status, indicating ‘no-show’ to 
test, may also reflect worse compliance to physicians coun-
selling, also resulting in suboptimal adherence and subse-
quent slower viral suppression in this group of patients [25].
Table 3  Number of persons 
who stopped first regimen and 
reasons for stopping
InSTI NNRTI PI Total
N % N % N % N %
Started treatment 7 100 44 100 65 100 116 100
Stopped or swapped regimen (ALL) 0 0 7 16 10 15 17 15
Reason for stopping N (% of those who stopped)
 ARV toxicity 0 0 1 14 8 80 9 53
 ARV failure 0 0 0 0 0 0 0 0
 Patient’s decision or non-adherence 0 0 2 29 1 10 3 18
 Other or unknown 0 0 0 0 1 10 1 6
 Hypersensitivity 0 0 4 57 0 0 4 24
Stopped regimen and did not restart 0 0 1 14 1 10 2 12
Reason for stopping N (% of those who stopped)
 ARV toxicity 0 0 1 100 0 0 1 50
 Patient’s decision or non-adherence 0 0 0 0 1 100 1 50
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Although genotyping is routinely performed in most of 
patients before starting cART these data were not collected 
in this study. Therefore, we cannot determine the role of 
drug resistance in response to treatment. However, Poland is 
a country with low prevalence of primary HIV drug resist-
ance [26, 27]. In addition, our data are confirmed by other 
Polish analyses showing an initial response to first cART of 
over 90% [4].
There are some limitations of this study which need to be 
mentioned. Due to short time of follow-up, we were not able 
to investigate longer term adherence to cART and retention 
in care. This is an important issue in public health and with 
increasing follow-up in TAK cohort we plan to investigate 
it. Secondly, most of our study population is men having sex 
with men and our findings may not be generalisable to pop-
ulations with higher representation of women or injecting 
drug users. In addition, it is important to note that linkage 
to care was comparatively low compared to the proportion 
starting cART or responding to cART, and it is likely that 
patients linked to care have self-selected to engage in HIV 
care, and the high proportions starting cART and responding 
to cART reflect this. Finally our multivariate model includes 
18 estimated parameters and is based on a sample size of 
113 individuals, therefore we cannot completely rule out the 
possibility that this model has been over-fitted. In addition, 
given that only three people failed to achieve virological 
suppression it needs to be underlined that the power to detect 
differences between the groups might be limited.
Viral suppression is required to prevent sexual HIV trans-
mission, therefore the shortest time to achieving viral sup-
pression provides the shortest window of opportunities for 
onward disease transmission [1]. In this perspective, bet-
ter understanding of factors influencing time to viral sup-
pression is crucial for controlling the epidemic [28]. In our 
earlier work, we have shown that the percentage of patient 
linked to care did not imrpove over calendar years, while 
the time to starting treatment shortened and the percentage 
of patients who started cART within 1 year from their first 
visit in the clinic increased [9]. Here we present that not 
only the time to starting cART, but also the time to achiev-
ing supressed viremia has improved over recent years. This 
can be contributed to substantial change in the understand-
ing of early cART benefit resulting in physicians initiating 
treatment irrespective of CD4 count [29, 30]. In addition, 
wider access to InSTI and one tablet regimens in Poland has 
facilitated the availability of regimens with better tolerability 
and reduced pill burden, which may partially contribute to 
this effect. As a result, the relative benefit received from 
being linked to care, defined as decreasing morbidity and 
HIV transmission risk, has substantially increased over the 
recent years.
However, looking at the TAK cascade of care in a step-
wise perspective we can see a necessity for improvement 
from the public health perspective. The current healthcare 
system in Poland is ready to respond to the HIV epidemic 
with early treatment and high suppression rates, but inter-
ventions increasing the number of people who are aware of 
their HIV status and assuring they are under specialist care 
and engage with such care should be a priority. To achieve 
any significant impact on the epidemic, scaling up HIV test-
ing and linkage to care followed by timely cART initiation 
must be considered as a holistic action. The modelling study 
by Phillips et al. suggests that using condoms and effective 
cART had only a limited effect on the HIV epidemic, until 
combined with much higher rates of HIV testing [31]. This 
indicates the importance of close collaboration between 
often structurally separated agencies and stakeholders [6, 
32]. The cascade of care is a helpful tool in this process 
allowing to both tailor and evaluate interventions. This war-
rants further investigation and supervision of linkage to care.
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